flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

De 2019 Dr. Paul Janssen Award voor Biomedisch Onderzoek voor F.-Ulrich Hartl en Arthur Horwich

F.-Ulrich Hartl, directeur van het Max Planck Institute of Biochemistry, en Arthur Horwich van Yale School of Medicine en Howard Hughes Medical Institute werden uitgeroepen tot winnaars van de 2019 Dr. Paul Janssen Award voor Biomedisch Onderzoek. Hartl en Horwich werden geselecteerd door een onafhankelijk comité van wereldvermaarde wetenschappers en wonnen voor hun baanbrekend inzicht in door chaperonne gemedieerde vouwing van eiwitten. Hartl sprak zijn voldoening uit te zijn verkozen als één van winnaars van de Dr. Paul Janssen Award. "Dit is een fantastische eer en erkenning van het werk van mijn laboratorium", zei hij. De award omvat een geldprijs van $ 200.000 en wordt in september uitgereikt tijdens plechtigheden in de VS en in België.

Development of a new leishmaniasis drug wins EU funding

TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.

Gilead and Galapagos enter into transformative research and development collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform.

FDA approves new cancer drug associated with KU Leuven discovery

The Food and Drug Administration in the United States of America has approved XPOVIOTM (also known as selinexor), a medicine for patients with relapsed refractory multiple myeloma, a type of bone marrow cancer. Around 230,000 people worldwide suffer from this rare disease. Selinexor was developed by Karyopharm Therapeutics Inc. based on inhibitors discovered at KU Leuven.

flanders.bio events, trainings & international missions

Strategic Partners